Cargando…

The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review

Objective: Sodium glucose cotransporter 2 inhibitors (SGLT2-is) are antidiabetic drugs that improve glycemic control by limiting urinary glucose reuptake in the proximal tubule. SGLT2-is might suppress atherosclerotic processes and ameliorate the prognosis of patients with diabetes mellitus diagnose...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pahud de Mortanges, Aurélie, Salvador Jr., Dante, Laimer, Markus, Muka, Taulant, Wilhelm, Matthias, Bano, Arjola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602558/ https://www.ncbi.nlm.nih.gov/pubmed/34803693 http://dx.doi.org/10.3389/fphar.2021.751214

Ejemplares similares

GLP-1 Receptor Agonists and Coronary Arteries: From Mechanisms to Events
por: Pahud de Mortanges, Aurélie, et al.
Publicado: (2022)

Impact of type 2 diabetes on life expectancy and role of kidney disease among inpatients with heart failure in Switzerland: an ambispective cohort study
por: Salvador, Dante, et al.
Publicado: (2023)

Physical performance and glycemic control under SGLT-2-inhibitors in patients with type 2 diabetes and established atherosclerotic cardiovascular diseases or high cardiovascular risk (PUSH): Design of a 4-week prospective observational study
por: Frundi, Devine S., et al.
Publicado: (2022)

Association of diabetes with atrial fibrillation types: a systematic review and meta-analysis
por: Alijla, Fadi, et al.
Publicado: (2021)

Comparison of different software for processing physical activity measurements with accelerometry
por: Verhoog, Sanne, et al.
Publicado: (2023)

Impact of Persistent Medication Adherence and Compliance with Lifestyle Recommendations on Major Cardiovascular Events and One-Year Mortality in Patients with Type 2 Diabetes and Advanced Stages of Atherosclerosis: Results From a Prospective Cohort Study
por: Shalaeva, Evgeniya V., et al.
Publicado: (2023)

Editorial: Pharmacoepidemiology in Diabetes Mellitus and its Complications: Focus on Response to Medications
por: Mohammadi Jouabadi, Soroush, et al.
Publicado: (2022)

A 7-Step Guideline for Qualitative Synthesis and Meta-Analysis of Observational Studies in Health Sciences
por: Glisic, Marija, et al.
Publicado: (2023)

Prognostic Role of Polyvascular Involvement in Patients with Symptomatic Peripheral Artery Disease
por: Adam, Luise, et al.
Publicado: (2023)

Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
por: Wicik, Zofia, et al.
Publicado: (2022)

Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches
por: Zhang, Yu, et al.
Publicado: (2023)

Exploratory Analysis of Qualitative MR Imaging Features for the Differentiation of Glioblastoma and Brain Metastases
por: Meier, Raphael, et al.
Publicado: (2020)

Anti-Inflammatory Effects of Thymoquinone in Atherosclerosis: A Mini Review
por: Leong, Xin-Fang, et al.
Publicado: (2021)

Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model
por: Demin, Oleg, et al.
Publicado: (2014)

Early menopause and cardiovascular risk factors: a cross-sectional and longitudinal study
por: Roa-Díaz, Zayne Milena, et al.
Publicado: (2023)

Editorial: Clinical prospective of SGLT2 inhibitors in atherosclerosis
por: Capuano, Annalisa, et al.
Publicado: (2022)

Oat Intake and Risk of Type 2 Diabetes, Cardiovascular Disease and All-Cause Mortality: A Systematic Review and Meta-Analysis
por: Wehrli, Faina, et al.
Publicado: (2021)

Machine Learning in Antibody Diagnostics for Inflammatory Bowel Disease Subtype Classification
por: Sokollik, Christiane, et al.
Publicado: (2023)

Coronary artery calcium score and coronary computed tomography angiography predict one-year mortality in patients with type 2 diabetes and peripheral artery disease undergoing partial foot amputation
por: Shalaeva, Evgeniya, et al.
Publicado: (2022)

Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS
por: Zhou, Xiang, et al.
Publicado: (2021)

Sodium-glucose cotransporter–2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis
por: Mascolo, Annamaria, et al.
Publicado: (2023)

Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans
por: Lu, Yasong, et al.
Publicado: (2014)

Cost-effectiveness analysis of alternative anticoagulation in suspected heparin-induced thrombocytopenia
por: Tuleja, Aleksandra, et al.
Publicado: (2022)

SGLT2 inhibitors for patients with heart failure with preserved ejection fraction in China: a cost-effectiveness study
por: Lu, He, et al.
Publicado: (2023)

Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China
por: Jiang, Yaohui, et al.
Publicado: (2021)

Buckwheat and Cardiometabolic Health: A Systematic Review and Meta-Analysis
por: Llanaj, Erand, et al.
Publicado: (2022)

Sex and N-terminal pro B-type natriuretic peptide: The potential mediating role of iron biomarkers
por: Khatami, Farnaz, et al.
Publicado: (2022)

A SGLT2 Inhibitor Dapagliflozin Alleviates Diabetic Cardiomyopathy by Suppressing High Glucose-Induced Oxidative Stress in vivo and in vitro
por: Xing, Yu-jie, et al.
Publicado: (2021)

Emerging Roles of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Cardiovascular Diseases: Focusing on Immunity, Inflammation and Metabolism
por: Xie, Lingxiang, et al.
Publicado: (2022)

Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review
por: Rabizadeh, Soghra, et al.
Publicado: (2019)

The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile
por: Aragón-Herrera, Alana, et al.
Publicado: (2022)

Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: A pharmacovigilance study of the FAERS database
por: Zhao, Hui, et al.
Publicado: (2023)

Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies
por: Li, Chun Xing, et al.
Publicado: (2023)

Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
por: Zhao, Li-Min, et al.
Publicado: (2022)

The Outcomes of Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2I) on Diabetes-Associated Neuropathy: A Systematic Review and meta-Analysis
por: Kandeel, Mahmoud
Publicado: (2022)

Reduced-Exertion High-Intensity Interval Training as a Novel Therapeutic Approach for Insomnia
por: Atef, Hady, et al.
Publicado: (2021)

Misleading Meta-Analyses during COVID-19 Pandemic: Examples of Methodological Biases in Evidence Synthesis
por: Llanaj, Erand, et al.
Publicado: (2022)

Clinical evidence for high-risk medical devices used to manage diabetes: protocol for a systematic review and meta-analysis
por: Bano, Arjola, et al.
Publicado: (2023)

Effects and mechanisms of SGLT2 inhibitors on the NLRP3 inflammasome, with a focus on atherosclerosis
por: Yang, Liu, et al.
Publicado: (2022)

Pathophysiological basis of the cardiological benefits of SGLT-2 inhibitors: a narrative review
por: Panico, Cristina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_li5upq8k6q3nlmkrci5a52nnff